Company Overview and News


Add KITE
to your dashboard

Headline News

Omeros Corporation: What The Positive EMA's Opinion Regarding OMS-721 Orphan Status Entails

4h seekingalpha
In 2017, the aforesaid molecule gained the FDA designation as the potential orphan drug and breakthrough therapy for IgA nephropathy. The agency also fast-tracked it for aHUS. (66-0)

What Can We Expect From Gilead?

10h seekingalpha
Even after the Kite Pharma deal, Gilead has a lot of cash on hand that it could use for further M&A activities. (13-0)

Big Drugmakers Pay Big Prices for Promising Biotechs - WSJ

16h wsj
A pair of multibillion-dollar biotech deals announced Monday commanded hefty premiums, driven by big drugmakers’ need for new sources of revenue amid a scarcity of quality assets. (141-0)

Biotech's $20 billion Merger Monday sparks hope for more deals

16h cnbc
Three weeks into 2018, deal activity in the biotech sector is already almost halfway to what it was in 2017, at least in terms of size. (29-0)

NantHealth: A Promising Individualized Medicine Company

17h seekingalpha
Founded by the highly successful physician entrepreneur, Patrick Shoon-Xiong, NantHealth is servicing the new market of individualized medicine. (63-1)

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

19h in.reuters
(Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for haemophilia and cancer to their medicine cabinets. (42-0)

Biotech M&A takes off as Sanofi and Celgene spend US$20 billion - Channel NewsAsia

20h channelnewsasia
LONDON: Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than US$20 billion to add new products for hemophilia and cancer to their medicine cabinets. (30-0)

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

20h reuters
LONDON (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets. (30-0)

Gilead Aims To Take A Giant Lead In The CAR-T Space

2018-01-22 seekingalpha
Gilead Sciences creates a collaboration agreement with Pfizer to enhance CAR-T therapy with another immunotherapy drug built to spur T-cell immune response. (85-0)

3 Things In Biotech You Should Learn Today: January 20, 2018

2018-01-21 seekingalpha
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. (13-1)

China's Push Into Gene Therapy Targets Biotech's 1% - Bloomberg

2018-01-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (87-0)

Juno Therapeutics: What The Celgene Potential Acquisition Foretells

2018-01-19 seekingalpha
It's prudent to take some profits while keeping the rest of one's shares for further upsides. (120-2)

Sector Report: How The Pressure On Generic Drugs Is Creating Tailwind For Branded Molecules

2018-01-19 seekingalpha
"If you hope to have more money tomorrow than you have today, you've got to put a chunk of your assets into stocks. Sooner or later, a portfolio of stocks or stock mutual funds will turn out to be a lot more valuable than a portfolio of bonds or CDs or money-market funds." - Peter Lynch (124-1)

Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive

2018-01-19 investorplace
Celgene Corp. (NASDAQ:CELG), best known for the psoriasis medicine Otezla and a number of cancer drugs, like Revlimid and Vidaza, sent the stock of Juno Therapeutics Inc. (NASDAQ:JUNO) up 55% on Jan. 17 when it was reported to be buying it. An acquisition probably won’t change a lot for CELG stock. (81-0)

Bellicum Pharmaceuticals: CAR-T Play With Catalysts In 2018

2018-01-19 seekingalpha
The acquisition of Cell Design Labs by Gilead is proof that preclinical assets in the CAR-T space hold value. (98-1)

CUSIP: 49803L109